Phase 2 Lung Cancer Trial, Recruiting NCT06929936 Sponsor: The First Affiliated Hospital of Xiamen University Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT06929936
Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 or older, of any gender
  • People diagnosed with stage IV non-small cell lung cancer (a type of lung cancer) whose disease has not responded to at least one previous standard treatment — with specific prior treatment requirements depending on whether certain gene mutations are present in the cancer (confirm with trial site)
  • People whose cancer has at least one measurable tumour, as assessed using standard imaging guidelines
  • People whose blood test results meet specific thresholds for red blood cells, white blood cells, platelets, kidney function, liver function, and protein levels (confirm with trial site for exact values)
  • People with a general health and activity level rated 0–2 on a standard scale used by doctors (meaning able to carry out at least some self-care)
  • People with an expected survival of at least 3 months
  • Women who could become pregnant must have a negative pregnancy blood test before joining, and must use reliable contraception from signing the consent form until 3 months after the last dose
  • People who understand and are willing to sign the informed consent form

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have previously been treated with the chemotherapy drug docetaxel
  • People diagnosed with another cancer (other than non-small cell lung cancer) within the past 5 years — though certain skin cancers that were fully treated or removed may be exceptions (confirm with trial site)
  • People with uncontrolled heart disease affecting blood flow, or significant heart failure classified at a severe level
  • People who have had a stroke or major heart or blood vessel event in the 6 months before joining
  • People with a specific abnormality in heart rhythm (measured on an ECG) above certain thresholds, including a different threshold for those with a ventricular pacemaker (confirm with trial site)
  • People with HIV or known syphilis infection
  • People who have previously had a bone marrow or stem cell transplant
  • People who have a known allergy to the study drug or any of its ingredients
  • People the trial doctors consider unsuitable for the study for other reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
The First Affiliated Hospital of Xiamen University
Registry
ClinicalTrials.gov
Start date
9 May 2025
Est. completion
1 May 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of grade ≥ 3 neutropenia during chemotherapy treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov